New pill combo aims to fight stomach cancer when first treatment fails
NCT ID NCT07552402
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests whether taking oral paclitaxel plus fruquintinib can help people with advanced stomach or gastroesophageal junction cancer after their first treatment stops working. About 150 adults will receive either the new drug combo or standard chemotherapy chosen by their doctor. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral paclitaxel solution plus fruquintinib
What this could lead to
If successful, this could provide a new second-line treatment option for advanced gastric cancer, potentially slowing tumor growth and improving survival.
What could go wrong
This is an early-stage trial with only 150 participants, so results may not apply to all patients. The combination may cause side effects like toxicity, and it may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baotou Cancer Hospital
RECRUITINGBaotou, Inner Mongolia, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Hospital of Dalian Medical University
RECRUITINGDalian, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••